MDWD

MediWound Ltd. (MDWD) | Rumor.io

MediWound

MDWD

Attention (50-day avg)0%

Attention rank (50-day avg)#3,537

Bullish sentiment (50-day avg)100%

Price to earnings ratio-6.63

Market capitalization179.8M

Earnings per share-2.16

Dividend yield (TTM)—

Revenue (annual)17M

Net income (annual)-23.9M

Social

What share of all stock conversation is about MDWD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

MediWound's Q1 2026 results show revenue deceleration to $1.5M (down 63% YoY) due to manufacturing limits and external shocks.
The company reaffirmed its full-year 2026 revenue guidance at $24M to $26M, supported by expected revenue from government-related development services.
MediWound's Q1 EPS beat estimates, but revenue missed expectations, with the company's pipeline and guidance being key to determining the direction of the stock.

Generated by AI

Sentiment

Of the messages about MDWD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.24% +1.51
Bearish	—	—	—	4.76% -1.51

Bullish· Jul 5

$MDWD has shown strong price action, with a spike to 24 and extension targets of 22 and 23.75+.
The asset has demonstrated a strong bullish trend, with multiple traders exiting positions at a 20% profit and expecting further gains.
A buyout at $34 is rumored to be imminent, with many traders expecting $MDWD to trade higher due to this news.

Bearish· Jul 5

$MDWD's price movement may be driven by profit takers, with potential support at $30.
The stock's recent price surge may be a result of a fake takeover offer, which could lead to a significant price drop.
The company's market capitalization is only $250M, making a $34 price target seem unrealistic and potentially unsustainable.

Generated by AI

Topics

Of the messages about MDWD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.98%
Macro	—	—	0%	4.69%
Analysts	—	—	0%	9.77%
Controversies	—	—	0%	1.17%
Earnings	—	—	0%	0%
Technical Analysis	—	—	0%	0.39%

Dec 29

MediWound Ltd. (MDWD) received FDA approval for its product NexoBrid to treat severe thermal burns in adults.
This approval triggers a $7.5M milestone payment from Vericel Corp. (VCEL) to MDWD.
NexoBrid is already approved for use in 43 countries, with VCEL holding an exclusive license for North America.

Generated by AI

Community

Of the messages about MDWD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	62.5%	77.33%
Newcomers	—	—	37.5%	22.67%

Regulars· May 30

MediWound Ltd. reported a Q1 2023 loss of $0.44 per share, missing the consensus estimate by $0.07 per share.
The company's revenue of $3.80 million missed the consensus estimate by $1.35 million, with the CEO citing market and competition factors.
MediWound expects to launch its NexoBrid product in the third quarter of 2023, following FDA approval for the treatment of severe burns.

Newcomers· Dec 13

MediWound Ltd. ($MDWD) has gained approval in India for its NexoBrid product, expanding its global presence.
The stock price has reacted positively, with a $0.07 (5.79%) increase, but also experienced a dip of $-0.09 (-7.08%) due to market fluctuations.
Newcomers are taking note of MediWound's expanding global presence, with several breaking news posts highlighting the company's growth and approval in India.

Generated by AI

WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it

8d agoBenzinga

MediWound receives $3.3M from DoD for NexoBrid development

8d agoInvesting.com

MediWound at H.C. Wainwright: value trial looms as catalyst

15d agoInvesting.com

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)

16d agoYahoo Finance

Also Discussed

Investors talking about MDWD also mention

#	Name	Attention
1	Sol-Gel Technologies Ltd.SLGL	0%0
2	Kamada Ltd.KMDA	0%0
3	Vericel CorporationVCEL	0%0
4	Eton Pharmaceuticals, Inc.ETON	0%-0.01
5	Lineage Cell Therapeutics Inc.LCTX	0%-0.01
6	PRVB - Provention Bio, Inc.	——
7	ALBO - Albireo Pharma, Inc.	——
8	PRTK - Paratek Pharmaceuticals, Inc.	——
9	Evogene Ltd.EVGN	0%new
10	BLCM - Bellicum Pharmaceuticals, Inc.	——

MediWound Ltd.

Healthcare
Biotechnology

MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair. MediWound develops, manufactures, and commercializes products designed to address severe burns, chronic wounds, and other hard-to-heal tissue injuries. Its portfolio centers on biologic and protein-based treatments that selectively remove damaged tissue while preserving healthy tissue, supporting cleaner wound bed preparation and recovery care. The company serves hospitals, burn centers, and other healthcare providers involved in acute and specialized wound management. MediWound also works across tissue regeneration and related therapeutic areas, positioning itself within the broader wound care and regenerative medicine market. Headquartered in Yavne, Israel, MediWound emphasizes advanced, clinically focused solutions that aim to improve treatment workflows in modern wound care settings.

Website

Location

42 Hayarkon Street

Yavne, 8122745

Israel

Social

What share of all stock conversation is about MDWD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 27

MediWound's Q1 2026 results show revenue deceleration to $1.5M (down 63% YoY) due to manufacturing limits and external shocks.
The company reaffirmed its full-year 2026 revenue guidance at $24M to $26M, supported by expected revenue from government-related development services.
MediWound's Q1 EPS beat estimates, but revenue missed expectations, with the company's pipeline and guidance being key to determining the direction of the stock.

Generated by AI

Sentiment

Of the messages about MDWD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.24% +1.51
Bearish	—	—	—	4.76% -1.51

Bullish· Jul 5

$MDWD has shown strong price action, with a spike to 24 and extension targets of 22 and 23.75+.
The asset has demonstrated a strong bullish trend, with multiple traders exiting positions at a 20% profit and expecting further gains.
A buyout at $34 is rumored to be imminent, with many traders expecting $MDWD to trade higher due to this news.

Bearish· Jul 5

$MDWD's price movement may be driven by profit takers, with potential support at $30.
The stock's recent price surge may be a result of a fake takeover offer, which could lead to a significant price drop.
The company's market capitalization is only $250M, making a $34 price target seem unrealistic and potentially unsustainable.

Generated by AI

Topics

Of the messages about MDWD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	83.98%
Macro	—	—	0%	4.69%
Analysts	—	—	0%	9.77%
Controversies	—	—	0%	1.17%
Earnings	—	—	0%	0%
Technical Analysis	—	—	0%	0.39%

Dec 29

MediWound Ltd. (MDWD) received FDA approval for its product NexoBrid to treat severe thermal burns in adults.
This approval triggers a $7.5M milestone payment from Vericel Corp. (VCEL) to MDWD.
NexoBrid is already approved for use in 43 countries, with VCEL holding an exclusive license for North America.

Generated by AI

Community

Of the messages about MDWD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	62.5%	77.33%
Newcomers	—	—	37.5%	22.67%

Regulars· May 30

MediWound Ltd. reported a Q1 2023 loss of $0.44 per share, missing the consensus estimate by $0.07 per share.
The company's revenue of $3.80 million missed the consensus estimate by $1.35 million, with the CEO citing market and competition factors.
MediWound expects to launch its NexoBrid product in the third quarter of 2023, following FDA approval for the treatment of severe burns.

Newcomers· Dec 13

MediWound Ltd. ($MDWD) has gained approval in India for its NexoBrid product, expanding its global presence.
The stock price has reacted positively, with a $0.07 (5.79%) increase, but also experienced a dip of $-0.09 (-7.08%) due to market fluctuations.
Newcomers are taking note of MediWound's expanding global presence, with several breaking news posts highlighting the company's growth and approval in India.

Generated by AI

MediWound

Social

May 27

Sentiment

Bullish· Jul 5

Bearish· Jul 5

Topics

Dec 29

Community

Regulars· May 30

Newcomers· Dec 13

News

Chronic Wounds Pipeline 2026: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE

TD Cowen reiterates MediWound stock rating ahead of trial data

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

MediWound receives $3.3M from DoD for NexoBrid development

MediWound at H.C. Wainwright: value trial looms as catalyst

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Also Discussed

MediWound Ltd.

Company Information

Location

News

Chronic Wounds Pipeline 2026: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE

TD Cowen reiterates MediWound stock rating ahead of trial data

Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

MediWound receives $3.3M from DoD for NexoBrid development

MediWound at H.C. Wainwright: value trial looms as catalyst

Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

Also Discussed

Social

May 27

Sentiment

Bullish· Jul 5

Bearish· Jul 5

Topics

Dec 29

Community

Regulars· May 30

Newcomers· Dec 13